Live Breaking News & Updates on University In Frankfurt Am Main

Stay updated with breaking news from University in frankfurt am main. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Phoenix Cardiac Receives CE Mark for its Innovative BACE Device to Treat Functional Mitral Regurgitation


Phoenix Cardiac Receives CE Mark for its Innovative BACE Device to Treat Functional Mitral Regurgitation
Company seeks partner to conduct a pivotal study in pursuit of a heart failure indication
Clinical data supporting CE Mark to be presented as a late-breaking oral presentation at the virtual AATS 101
st annual meeting
CARY, N.C., April 26, 2021 /PRNewswire/ Phoenix Cardiac Devices, Inc., an innovator in cardiovascular medical device research and development, today announced that it has received CE Mark for its BACE (Basal Annuloplasty of the Cardia Externally) device, a novel modality for the treatment of Functional Mitral Regurgitation (FMR). BACE is the only surgical device with long-term clinical data demonstrating significant benefit by addressing the root cause of FMR. The CE Mark serves as approval by the European Union (EU) to commercialize BACE. The supporting clinical data, showing significant efficacy in reduction of MR grade and size of the left ven ....

United States , Andhra Pradesh , Jan Hlavicka , Kostenloser Wertpapierhandel , Gopal Muppirala , Phoenix Cardiac Devices Inc , University Hospital Clinic For Cardiovascular Surgery , Phoenix Cardiac Inc , University In Frankfurt Am Main , Prnewswire Phoenix Cardiac Devices Inc , American Association For Thoracic Surgery , European Union , Cardiac Devices , Basal Annuloplasty , Cardia Externally , Functional Mitral Regurgitation , American Association , Thoracic Surgery , Chief Executive Officer , Phoenix Cardiac , University Hospital Clinic , Cardiovascular Surgery , Functional Mitral , Phoenix Cardiac Devices , Chief Executive Officer Gopal Muppirala , Chief Scientific Officer Jai Raman ,

Research reveals vital clues for discovery of COVID-19 drugs


Research reveals vital clues for discovery of COVID-19 drugs
Research from the University of Kent, Goethe-University in Frankfurt am Main, and the Philipps-University in Marburg has provided crucial insights into the biological composition of SARS-CoV-2, the cause of COVID-19, revealing vital clues for the discovery of antiviral drugs.
Researchers compared SARS-CoV-2 and the closely related virus SARS-CoV, the cause of the 2002/03 SARS outbreak. Despite being 80% biologically identical, the viruses differ in crucial properties. SARS-CoV-2 is more contagious and less deadly, with a fatality rate of 2% compared to SARS-CoV s 10%. Moreover, SARS-CoV-2 can be spread by asymptomatic individuals, whereas SARS-CoV was only transmitted by those who were already ill. ....

Martin Michaelis , Jindrich Cinatl , Emily Henderson , University Of Kent , Kent School Of Biosciences , University In Marburg , University In Frankfurt Am Main , Molecular Medicine , Amino Acid , Medical School , Sars Cov 2 , மார்டின் மைக்கேலிஸ் , எமிலி ஹென்டர்சன் , பல்கலைக்கழகம் ஆஃப் கேண்ட் , கேண்ட் பள்ளி ஆஃப் உயிர் அறிவியல் , பல்கலைக்கழகம் இல் மார்பர்க் , பல்கலைக்கழகம் இல் பிராங்க்ஃபர்ட் நான் பிரதான , மூலக்கூறு மருந்து , அமினோ அமிலம் , உயிர் தகவலியல் , மருத்துவ பள்ளி ,